Dr. Thomas Kim, President and CEO of EpiVario, a preclinical pharmaceutical company, discusses the study published in “Nature” (Oct 2019) titled “Alcohol metabolism contributes to brain histone acetylation”. This new research is the first empirical evidence indicating a direct link between alcohol consumption and the memory formation process. Mice tested during the study showed a preference for alcohol when exposed to environmental cues to consume alcohol; and when this metabolic route was blocked, via the ACSS2 enzyme, this preference was eliminated. These new findings could pave the way for novel therapeutic interventions for alcohol use, fetal alcohol syndrome, and other neuropsychiatric disorders.
Thomas Kim is an experienced biotech executive and corporate attorney, and a registered patent attorney. He has lead EpiVario Inc. from a University of Pennsylvania startup in 2017, to a seed-funded, preclinical drug development company. He previously served as SVP and Corporate Secretary for a public biopharmaceutical company, Inovio Pharmaceuticals. Dr. Kim has counseled pharmaceutical and biotechnology companies for over 20 years. He has practiced law at two large law firms and at Fortune 100 companies including Monsanto and DuPont.